表紙
市場調查報告書

神經調節的全球市場預測 2025年:內部神經調節 (脊髓刺激法、腦深部刺激法、迷走神經刺激法、薦椎神經刺激法、胃電刺激法),外部神經調節 (經皮電力神經刺激法 (TENS)、經顱磁刺激法 (TMS)、呼吸電刺激法)

Neuromodulation Market by Technology - Internal (Deep Brain Stimulation, Vagus Nerve Stimulation), External (Transcranial Magnetic Stimulation), Application - Global Forecast to 2025

出版商 MarketsandMarkets 商品編碼 927108
出版日期 內容資訊 英文 157 Pages
訂單完成後即時交付
價格
神經調節的全球市場預測 2025年:內部神經調節 (脊髓刺激法、腦深部刺激法、迷走神經刺激法、薦椎神經刺激法、胃電刺激法),外部神經調節 (經皮電力神經刺激法 (TENS)、經顱磁刺激法 (TMS)、呼吸電刺激法) Neuromodulation Market by Technology - Internal (Deep Brain Stimulation, Vagus Nerve Stimulation), External (Transcranial Magnetic Stimulation), Application - Global Forecast to 2025
出版日期: 2020年02月28日內容資訊: 英文 157 Pages
簡介

全球神經調節市場規模預測將從2020年的58億美元,到2025年達到88億美元,在預測期間中預計將以8.6%的年複合成長率成長。促進該市場成長的主要原因,是神經病變的盛行率上升,擴大神經調節的應用的研究增加,及神經退化性疾病的認識等。可是,技術純熟勞工的不足,神經調節治療、設備的成本高,成為對市場成長來說的課題。各技術中,內部神經調節市場區隔在預測期間內,預計將以最高年複合成長率成長。這個成長,主要由於術後併發症的降低和住院期間的縮短,以及內部神經調節設備相關的長期性的降低成本而受到促進。各地區中,預計亞太地區,由於主要神經病變的發生率高,公民營投資的增加,及研究的繼續,在預測期間內將以最高年複合成長率成長。

本報告提供全球神經調節市場相關調查分析,各市場區隔及各地區的市場分析與預測,市場發展的影響要素,競爭環境,主要企業等相關之調查、分析。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

  • 神經調節市場:概要
  • 北美的神經調節市場:各技術
  • 全球脊髓刺激市場:各用途

第5章 市場概要

  • 簡介
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 機會
    • 課題

第6章 神經調節市場:各技術

  • 簡介
  • 內部神經調節
    • 脊髓刺激法
    • 腦深部刺激法
    • 迷走神經刺激法
    • 薦椎神經刺激法
    • 胃電刺激法
  • 外部神經調節
    • 經皮電力神經刺激法 (TENS)
    • 經顱磁刺激法 (TMS)
    • 呼吸電刺激法

第7章 神經調節市場:各用途

  • 簡介
  • 脊髓刺激法:各適應症
    • 慢性疼痛
    • 脊椎手術後痛症候群
    • 缺血
  • 深部腦刺激法:各適應症
    • 帕金森氏症
    • 顫動
    • 憂鬱症
    • 其他
  • 薦椎神經刺激法:各適應症
    • 尿失禁
    • 航班失禁
  • 迷走神經刺激法:各適應症
    • 癲癇
    • 其他
  • 胃電刺激法:各適應症
    • 胃輕癱
    • 肥胖
  • 經皮電力神經刺激法:各適應症
    • 治療反抗性憂鬱症
    • 其他
  • 經顱磁刺激法:各適應症
    • 憂鬱症
    • 偏頭痛
  • 呼吸電刺激法:各適應症
    • 脊髓損傷

第8章 神經調節市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 其他

第9章 競爭情形

  • 簡介
  • 市場佔有率分析
  • 競爭模式
  • 競爭領導製圖

第10章 神經調節市場:各產業

  • MEDTRONIC
  • BOSTON SCIENTIFIC CORPORATION
  • ABBOTT
  • LIVANOVA
  • NEVRO CORPORATION
  • NEUROSIGMA, INC.
  • NEUROPACE, INC.
  • BIOCONTROL MEDICAL
  • SYNAPSE BIOMEDICAL
  • NEURONETICS
  • BIONESS
  • SOTERIX MEDICAL
  • INTEGER HOLDINGS CORPORATION
  • BIOINDUCTION
  • 其他企業
    • GIMER MEDICAL
    • GTX MEDICAL
    • HELIUS MEDICAL TECHNOLOGIES
    • MICROTRANSPONDER
    • NEURONANO
    • BLUEWIND MEDICAL

第11章 附錄

目錄
Product Code: BT 3571

"The neuromodulation market is projected to grow at a CAGR of 8.6% during the forecast period (2020-2025)."

The global neuromodulation market size is projected to reach USD 8.8 billion by 2025 from USD 5.8 billion in 2020, at a CAGR of 8.6%. The growth of this market is driven majorly by factors such as the rising prevalence of neurological disorders, increasing research into expanding the applications of neuromodulation, and awareness on neurodegenerative disorders. However, the high cost of neuromodulation procedures and equipment, along with the dearth of a trained workforce, will challenge market growth.

"By technology, the internal neuromodulation segment is expected to grow at the highest CAGR during the forecast period."

Based on technology, the neuromodulation market is segmented into internal neuromodulation and external neuromodulation. The internal neuromodulation segment accounted for the largest market share in 2019. This segment is also expected to register the highest growth during the forecast period. This growth in this segment is driven primarily by reductions in post-surgical complications and length of hospital stay, as well as long-term cost savings associated with the use of internal neuromodulation devices.

"By type, the transcutaneous electrical nerve stimulation (TENS) segment dominated the external neuromodulation market in 2019."

Based on type, the external neuromodulation market is segmented into transcutaneous electrical nerve stimulation (TENS), transcranial magnetic stimulation (TMS), and respiratory electrical stimulation (RES). TENS accounted for the largest share of the external neuromodulation market in 2019, owing to the higher incidence of chronic disorders, the wide range of applications of these devices, their cost-effectiveness, and the rising demand for non-invasive therapy.

"Asia Pacific neuromodulation market is expected to witness the highest growth during the forecast period."

The Asia Pacific market is estimated to grow at the highest CAGR during the forecast period, primarily due to the high incidence of neurological disorders, increasing public and private investments, and ongoing research.

A breakdown of the primary participants referred to for this report is provided below:

  • By Company Type: Tier 1-36%, Tier 2-45%, and Tier 3-19%
  • By Designation: C-level-33%, Director-level-40%, and Others-27%
  • By Region: North America-36%, Europe-28%, Asia Pacific-19%, RoW-17%

The prominent players operating in the global neuromodulation market include: Medtronic (Ireland), Boston Scientific Corporation (US), Abbott (US), LivaNova (UK), Synapse Biomedical, Inc. (US), Nevro Corporation (US), NeuroSigma (US), NeuroPace (US), Neuronetics (US), and BioControl Medical (Israel).

Research Coverage:

The report analyzes the neuromodulation market and aims at estimating the market size and future growth potential. The report also includes an in-depth competitive analysis of the key players in this market, along with their company profiles, product offerings, and recent developments.

Reasons to Buy the Report:

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a greater share. Firms purchasing the report could use one, or a combination of the below mentioned five strategies for strengthening their market presence.

This report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the neuromodulation market
  • Service Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the neuromodulation market
  • Market Development: Comprehensive information on lucrative emerging regions
  • Market Diversification: Exhaustive information about new systems, growing geographies, and recent developments in the global neuromodulation market
  • Competitive Assessment:In-depth assessment of market shares, growth strategies, revenue analysis, and services of leading players in the neuromodulation market

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 MARKET SCOPE
    • 1.3.1 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 SECONDARY DATA
    • 2.2.1 SECONDARY SOURCES
  • 2.3 PRIMARY DATA
    • 2.3.1 KEY DATA FROM PRIMARY SOURCES
  • 2.4 MARKET SIZE ESTIMATION
    • 2.4.1 BOTTOM-UP APPROACH
    • 2.4.2 TOP-DOWN APPROACH
    • 2.4.3 GROWTH FORECAST
  • 2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.6 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 NEUROMODULATION: MARKET OVERVIEW
  • 4.2 NORTH AMERICA: NEUROMODULATION MARKET, BY TECHNOLOGY (2019)
  • 4.3 GLOBAL SPINAL CORD STIMULATION MARKET, BY APPLICATION

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising prevalence of neurological disorders
      • 5.2.1.2 Research into expanding the applications of neuromodulation
      • 5.2.1.3 Rising awareness on neurodegenerative disorders
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of neuromodulation procedures
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Expansion in emerging economies
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Dearth of trained professionals

6 NEUROMODULATION MARKET, BY TECHNOLOGY

  • 6.1 INTRODUCTION
  • 6.2 INTERNAL NEUROMODULATION
    • 6.2.1 SPINAL CORD STIMULATION
      • 6.2.1.1 Rising incidence of indications and efficacy & reversibility of procedure have supported the adoption of SCS
    • 6.2.2 DEEP BRAIN STIMULATION
      • 6.2.2.1 Increasing research has driven the development of advanced DBS systems
    • 6.2.3 VAGUS NERVE STIMULATION
      • 6.2.3.1 Rising disorder incidence and growing geriatric population are driving market growth
    • 6.2.4 SACRAL NERVE STIMULATION
      • 6.2.4.1 Effectiveness of SNS and rising incidence of urological disorders are the key growth drivers for this market
    • 6.2.5 GASTRIC ELECTRICAL STIMULATION
      • 6.2.5.1 GES is mainly used for the treatment of GERD and gastroparesis
  • 6.3 EXTERNAL NEUROMODULATION
    • 6.3.1 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION
      • 6.3.1.1 Extensive use in healthcare, low cost, and ease of use will favor market growth
    • 6.3.2 TRANSCRANIAL MAGNETIC STIMULATION
      • 6.3.2.1 Minimal patient discomfort associated with TMS has supported the demand for the technology
    • 6.3.3 RESPIRATORY ELECTRICAL STIMULATION
      • 6.3.3.1 Increasing incidence of spinal cord injuries and high treatment efficacy have driven market growth

7 NEUROMODULATION MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
  • 7.2 SPINAL CORD STIMULATION, BY APPLICATION
    • 7.2.1 CHRONIC PAIN
      • 7.2.1.1 High incidence of chronic pain supports market growth
    • 7.2.2 FAILED BACK SURGERY SYNDROME
      • 7.2.2.1 Rising incidence of FBSS has driven demand for stimulation technologies
    • 7.2.3 ISCHEMIA
      • 7.2.3.1 High incidence of ischemia and effectiveness of neuromodulation supports the growth of the market
  • 7.3 DEEP BRAIN STIMULATION, BY APPLICATION
    • 7.3.1 PARKINSON'S DISEASE
      • 7.3.1.1 Rising incidence of Parkinson's disease and growing R&D activity in this area are likely to drive market growth
    • 7.3.2 TREMORS
      • 7.3.2.1 High efficacy of DBS in treating tremors has boosted demand for the technology
    • 7.3.3 DEPRESSION
      • 7.3.3.1 Use of DBS in depression treatment is restrained by a lack of evidence for its efficacy
    • 7.3.4 OTHER DBS APPLICATIONS
  • 7.4 SACRAL NERVE STIMULATION MARKET, BY APPLICATION
    • 7.4.1 URINARY INCONTINENCE
      • 7.4.1.1 High incidence of urinary incontinence offers growth opportunities
    • 7.4.2 FECAL INCONTINENCE
      • 7.4.2.1 High reductions in symptom recurrence have supported the use of SNS in fecal incontinence treatment
  • 7.5 VAGUS NERVE STIMULATION, BY APPLICATION
    • 7.5.1 EPILEPSY
      • 7.5.1.1 Advantages associated with VNS in the treatment of epilepsy are expected to drive the market
    • 7.5.2 OTHER VNS APPLICATIONS
  • 7.6 GASTRIC ELECTRICAL STIMULATION, BY APPLICATION
    • 7.6.1 GASTROPARESIS
      • 7.6.1.1 GES treatment reduces hospital stay duration for patients affected by gastroparesis
    • 7.6.2 OBESITY
      • 7.6.2.1 High prevalence of obesity and benefits of GES are likely to drive the market
  • 7.7 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION
    • 7.7.1 TREATMENT-RESISTANT DEPRESSION
      • 7.7.1.1 High prevalence of depression is driving market growth
    • 7.7.2 OTHER TENS APPLICATIONS
  • 7.8 TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION
    • 7.8.1 DEPRESSION
      • 7.8.1.1 Effectiveness of this treatment method and its increased acceptance among patients are driving demand
    • 7.8.2 MIGRAINE
      • 7.8.2.1 High prevalence of migraine is expected to increase the demand for transcranial magnetic stimulation
  • 7.9 RESPIRATORY ELECTRICAL STIMULATION, BY APPLICATION
    • 7.9.1 SPINAL CORD INJURY
      • 7.9.1.1 High prevalence of spinal cord injury is likely to drive market growth in the future

8 NEUROMODULATION MARKET, BY REGION

  • 8.1 INTRODUCTION
  • 8.2 NORTH AMERICA
    • 8.2.1 US
      • 8.2.1.1 Rising prevalence of chronic diseases is expected to increase the demand for neuromodulation devices in the US
    • 8.2.2 CANADA
      • 8.2.2.1 Rising healthcare expenditure and increasing disease prevalence will drive demand for neurostimulation
  • 8.3 EUROPE
    • 8.3.1 GERMANY
      • 8.3.1.1 High healthcare expenditure and favorable government initiatives have ensured strong market growth in Germany
    • 8.3.2 UK
      • 8.3.2.1 High investment by public and private sectors play an important role in the growth of the neuromodulation market in the UK
    • 8.3.3 FRANCE
      • 8.3.3.1 Availability of insurance and favorable healthcare reforms have contributed to the growth of the French market
    • 8.3.4 ITALY
      • 8.3.4.1 Easy access to healthcare services has supported the use of neuromodulation in Italy
    • 8.3.5 SPAIN
      • 8.3.5.1 The growth of this market can be attributed to the increasing incidences of chronic diseases
    • 8.3.6 REST OF EUROPE
  • 8.4 ASIA PACIFIC
    • 8.4.1 JAPAN
      • 8.4.1.1 Japan dominates the APAC market for neuromodulation
    • 8.4.2 CHINA
      • 8.4.2.1 Infrastructural development, aging population, and rising disease incidence will favor market growth in China
    • 8.4.3 INDIA
      • 8.4.3.1 Improvements in healthcare infrastructure in the country will support the growth of the neuromodulation market
    • 8.4.4 REST OF ASIA PACIFIC
  • 8.5 REST OF THE WORLD
    • 8.5.1 LATIN AMERICA
      • 8.5.1.1 Latin America holds the largest share of the neuromodulation market in the RoW
    • 8.5.2 MIDDLE EAST & AFRICA
      • 8.5.2.1 The high cost of neuromodulation will hamper market growth in the region

9 COMPETITIVE LANDSCAPE

  • 9.1 OVERVIEW
  • 9.2 MARKET SHARE ANALYSIS, 2019
  • 9.3 COMPETITIVE SCENARIO
  • 9.4 COMPETITIVE LEADERSHIP MAPPING (OVERALL MARKET) (2019)
    • 9.4.1 VISIONARY LEADERS
    • 9.4.2 INNOVATORS
    • 9.4.3 DYNAMIC DIFFERENTIATORS
    • 9.4.4 EMERGING COMPANIES

10 COMPANY PROFILES

(Business Overview, Products Offered, Recent Developments, MnM View)*

  • 10.1 MEDTRONIC
  • 10.2 BOSTON SCIENTIFIC CORPORATION
  • 10.3 ABBOTT
  • 10.4 LIVANOVA
  • 10.5 NEVRO CORPORATION
  • 10.6 NEUROSIGMA, INC.
  • 10.7 NEUROPACE, INC.
  • 10.8 BIOCONTROL MEDICAL
  • 10.9 SYNAPSE BIOMEDICAL
  • 10.10 NEURONETICS
  • 10.11 BIONESS
  • 10.12 SOTERIX MEDICAL
  • 10.13 INTEGER HOLDINGS CORPORATION
  • 10.14 BIOINDUCTION
  • 10.15 OTHER PLAYERS
    • 10.15.1 GIMER MEDICAL
    • 10.15.2 GTX MEDICAL
    • 10.15.3 HELIUS MEDICAL TECHNOLOGIES
    • 10.15.4 MICROTRANSPONDER
    • 10.15.5 NEURONANO
    • 10.15.6 BLUEWIND MEDICAL

Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

11 APPENDIX

  • 11.1 DISCUSSION GUIDE
  • 11.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 11.3 AVAILABLE CUSTOMIZATIONS
  • 11.4 RELATED REPORTS
  • 11.5 AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: INDICATIVE LIST: NEUROMODULATION CLINICAL TRIALS
  • TABLE 2: NEUROMODULATION MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
  • TABLE 3: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 4: INTERNAL NEUROMODULATION MARKET, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 5: NORTH AMERICA: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 6: EUROPE: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 7: APAC: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 8: ROW: INTERNAL NEUROMODULATION MARKET, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 9: SPINAL CORD STIMULATION MARKET, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 10: SPINAL CORD STIMULATION MARKET, BY REGION, 2018-2025 (UNITS)
  • TABLE 11: NORTH AMERICA: SPINAL CORD STIMULATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 12: EUROPE: SPINAL CORD STIMULATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 13: APAC: SPINAL CORD STIMULATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 14: ROW: SPINAL CORD STIMULATION MARKET, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 15: DEEP BRAIN STIMULATION MARKET, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 16: DEEP BRAIN STIMULATION MARKET, BY REGION, 2018-2025 (UNITS)
  • TABLE 17: NORTH AMERICA: DEEP BRAIN STIMULATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 18: EUROPE: DEEP BRAIN STIMULATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 19: APAC: DEEP BRAIN STIMULATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 20: ROW: DEEP BRAIN STIMULATION MARKET, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 21: VAGUS NERVE STIMULATION MARKET, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 22: VAGUS NERVE STIMULATION MARKET, BY REGION, 2018-2025 (UNITS)
  • TABLE 23: NORTH AMERICA: VAGUS NERVE STIMULATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 24: EUROPE: VAGUS NERVE STIMULATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 25: APAC: VAGUS NERVE STIMULATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 26: ROW: VAGUS NERVE STIMULATION MARKET, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 27: SACRAL NERVE STIMULATION MARKET, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 28: SACRAL NERVE STIMULATION MARKET, BY REGION, 2018-2025 (UNITS)
  • TABLE 29: NORTH AMERICA: SACRAL NERVE STIMULATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 30: EUROPE: SACRAL NERVE STIMULATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 31: APAC: SACRAL NERVE STIMULATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 32: ROW: SACRAL NERVE STIMULATION MARKET, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 33: GASTRIC ELECTRICAL STIMULATION MARKET, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 34: GASTRIC ELECTRICAL STIMULATION MARKET, BY REGION, 2018-2025 (UNITS)
  • TABLE 35: NORTH AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 36: EUROPE: GASTRIC ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 37: APAC: GASTRIC ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 38: ROW: GASTRIC ELECTRICAL STIMULATION MARKET, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 39: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 40: EXTERNAL NEUROMODULATION MARKET, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 41: NORTH AMERICA: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 42: EUROPE: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 43: APAC: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 44: ROW: EXTERNAL NEUROMODULATION MARKET, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 45: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 46: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY REGION, 2018-2025 (UNITS)
  • TABLE 47: NORTH AMERICA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 48: EUROPE: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 49: APAC: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 50: ROW: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 51: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 52: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY REGION, 2018-2025 (UNITS)
  • TABLE 53: NORTH AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 54: EUROPE: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 55: APAC: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 56: ROW: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 57: RESPIRATORY ELECTRICAL STIMULATION MARKET, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 58: RESPIRATORY ELECTRICAL STIMULATION MARKET, BY REGION, 2018-2025 (UNITS)
  • TABLE 59: NORTH AMERICA: RESPIRATORY ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 60: EUROPE: RESPIRATORY ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 61: APAC: RESPIRATORY ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 62: ROW: RESPIRATORY ELECTRICAL STIMULATION MARKET, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 63: SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • TABLE 64: SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 65: SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 66: SPINAL CORD STIMULATION MARKET FOR ISCHEMIA, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 67: DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • TABLE 68: DEEP BRAIN STIMULATION MARKET FOR PARKINSON'S DISEASE, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 69: DEEP BRAIN STIMULATION MARKET FOR TREMORS, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 70: DEEP BRAIN STIMULATION MARKET FOR DEPRESSION, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 71: DEEP BRAIN STIMULATION MARKET FOR OTHER APPLICATIONS, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 72: SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • TABLE 73: SACRAL NERVE STIMULATION MARKET FOR URINARY INCONTINENCE, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 74: SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 75: VAGUS NERVE MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • TABLE 76: VAGUS NERVE STIMULATION MARKET FOR EPILEPSY, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 77: VAGUS NERVE STIMULATION MARKET FOR OTHER APPLICATIONS, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 78: GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • TABLE 79: GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 80: GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 81: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • TABLE 82: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 83: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR OTHER APPLICATIONS, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 84: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • TABLE 85: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 86: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 87: RESPIRATORY ELECTRICAL STIMULATION MARKET FOR SPINAL CORD INJURY, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 88: NEUROMODULATION MARKET, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 89: NORTH AMERICA: NEUROMODULATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 90: NORTH AMERICA: NEUROMODULATION MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
  • TABLE 91: NORTH AMERICA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 92: NORTH AMERICA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 93: NORTH AMERICA: SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • TABLE 94: NORTH AMERICA: DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • TABLE 95: NORTH AMERICA: SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • TABLE 96: NORTH AMERICA: VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • TABLE 97: NORTH AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • TABLE 98: NORTH AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • TABLE 99: NORTH AMERICA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • TABLE 100: US: NEUROMODULATION MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
  • TABLE 101: US: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 102: US: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 103: CANADA: NEUROMODULATION MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
  • TABLE 104: CANADA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 105: CANADA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 106: EUROPE: NEUROMODULATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 107: EUROPE: NEUROMODULATION MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
  • TABLE 108: EUROPE: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 109: EUROPE: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 110: EUROPE: SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • TABLE 111: EUROPE: DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • TABLE 112: EUROPE: SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • TABLE 113: EUROPE: VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • TABLE 114: EUROPE: GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • TABLE 115: EUROPE: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • TABLE 116: EUROPE: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • TABLE 117: GERMANY: NEUROMODULATION MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
  • TABLE 118: GERMANY: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 119: GERMANY: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 120: UK: NEUROMODULATION MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
  • TABLE 121: UK: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 122: UK: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 123: FRANCE: NEUROMODULATION MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
  • TABLE 124: FRANCE: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 125: FRANCE: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 126: ITALY: NEUROMODULATION MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
  • TABLE 127: ITALY: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 128: ITALY: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 129: SPAIN: NEUROMODULATION MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
  • TABLE 130: SPAIN: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 131: SPAIN: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 132: ROE: NEUROMODULATION MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
  • TABLE 133: ROE: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 134: ROE: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 135: ASIA PACIFIC: NEUROMODULATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 136: ASIA PACIFIC: NEUROMODULATION MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
  • TABLE 137: ASIA PACIFIC: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 138: ASIA PACIFIC: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 139: ASIA PACIFIC: SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • TABLE 140: ASIA PACIFIC: DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • TABLE 141: ASIA PACIFIC: SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • TABLE 142: ASIA PACIFIC: VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • TABLE 143: ASIA PACIFIC: GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • TABLE 144: ASIA PACIFIC: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • TABLE 145: ASIA PACIFIC: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • TABLE 146: JAPAN: NEUROMODULATION MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
  • TABLE 147: JAPAN: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 148: JAPAN: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 149: CHINA: NEUROMODULATION MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
  • TABLE 150: CHINA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 151: CHINA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 152: INDIA: NEUROMODULATION MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
  • TABLE 153: INDIA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 154: INDIA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 155: ROAPAC: NEUROMODULATION MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
  • TABLE 156: ROAPAC: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 157: ROAPAC: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 158: ROW: NEUROMODULATION MARKET, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 159: ROW: NEUROMODULATION MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
  • TABLE 160: ROW: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 161: ROW: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 162: ROW: SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • TABLE 163: ROW: DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • TABLE 164: ROW: SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • TABLE 165: ROW: VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • TABLE 166: ROW: GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • TABLE 167: ROW: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • TABLE 168: ROW: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • TABLE 169: LATIN AMERICA: NEUROMODULATION MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
  • TABLE 170: LATIN AMERICA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 171: LATIN AMERICA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 172: MEA: NEUROMODULATION MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
  • TABLE 173: MEA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 174: MEA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 175: AGREEMENTS AND PARTNERSHIPS (2017-2020)
  • TABLE 176: ACQUISITIONS (2017-2020)
  • TABLE 177: PRODUCT LAUNCHES AND APPROVALS (2017-2020)

LIST OF FIGURES

  • FIGURE 1: NEUROMODULATION MARKET
  • FIGURE 2: RESEARCH DESIGN
  • FIGURE 3: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4: MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
  • FIGURE 5: MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
  • FIGURE 6: DATA TRIANGULATION METHODOLOGY
  • FIGURE 7: NEUROMODULATION MARKET, BY TECHNOLOGY, 2020-2025
  • FIGURE 8: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2025
  • FIGURE 9: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2025
  • FIGURE 10: NEUROMODULATION MARKET: GEOGRAPHIC SNAPSHOT
  • FIGURE 11: RISING PREVALENCE OF NEUROLOGICAL DISORDERS WILL DRIVE THE GROWTH OF THE NEUROMODULATION MARKET
  • FIGURE 12: INTERNAL NEUROMODULATION ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN MARKET IN 2019
  • FIGURE 13: CHRONIC PAIN ACCOUNTS FOR THE LARGEST SHARE OF THE MARKET DURING THE FORECAST PERIOD
  • FIGURE 14: NEUROMODULATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 15: NORTH AMERICA: NEUROMODULATION MARKET SNAPSHOT
  • FIGURE 16: ASIA PACIFIC: NEUROMODULATION MARKET SNAPSHOT
  • FIGURE 17: KEY PLAYERS ADOPTED ORGANIC AS WELL AS INORGANIC GROWTH STRATEGIES BETWEEN 2017 AND 2020
  • FIGURE 18: MARKET RANKING OF KEY PLAYERS, 2019
  • FIGURE 19: COMPETITIVE LEADERSHIP MAPPING: NEUROMODULATION MARKET
  • FIGURE 20: MEDTRONIC: COMPANY SNAPSHOT
  • FIGURE 21: BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
  • FIGURE 22: ABBOTT: COMPANY SNAPSHOT
  • FIGURE 23: LIVANOVA: COMPANY SNAPSHOT
  • FIGURE 24: NEVRO CORPORATION: COMPANY SNAPSHOT
  • FIGURE 25: INTEGER HOLDINGS CORPORATION: COMPANY SNAPSHOT